Revolution Medicines (NASDAQ:RVMD) Issues Quarterly Earnings Results

Revolution Medicines (NASDAQ:RVMD) released its earnings results on Wednesday. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30), FiscalAI reports. During the same period in the prior year, the company earned ($1.12) EPS.

Here are the key takeaways from Revolution Medicines’ conference call:

• daraxonrasib registrational enrollment for RASolute‑302 is complete and an OS event‑driven top‑line readout is expected in the first half of 2026, potentially a major value inflection if positive.
• Zoldonrasib showed encouraging first‑line PDAC combo activity (63% partial response, 95% disease control rate in early data), and the company has initiated RESOLUTE‑305 with RASolute‑309 planned for H2 2026.
• RevMed now has a broad RAS(ON) portfolio — four clinical‑stage inhibitors (daraxonrasib, elironrasib, zoldonrasib, RMC‑5127), a preclinical resistance‑targeting class (RMC‑055) slated for clinical development, and >2,500 patients dosed across programs with eight ongoing/planned Phase III trials.
• Strong liquidity position with $2.03 billion in cash and investments and an innovative Royalty Pharma arrangement providing up to $2 billion in committed capital (first $250M tranche received), reducing near‑term financing risk.
• Spending is ramping materially: Q4 net loss was $364.9M and RevMed guided full‑year 2026 GAAP operating expenses of $1.6–$1.7 billion (including $180–$200M stock‑based comp), reflecting significantly higher R&D and commercial preparation costs that will increase near‑term cash burn.

Revolution Medicines Stock Performance

RVMD stock traded up $0.80 during trading on Friday, reaching $102.95. 1,058,930 shares of the stock were exchanged, compared to its average volume of 3,845,633. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $124.49. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock has a 50 day simple moving average of $98.72 and a 200-day simple moving average of $69.89. The company has a market capitalization of $19.90 billion, a P/E ratio of -17.42 and a beta of 1.01.

Insider Transactions at Revolution Medicines

In other news, COO Margaret A. Horn sold 75,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the sale, the chief operating officer directly owned 141,053 shares in the company, valued at $14,184,289.68. This trade represents a 34.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jack Anders sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total transaction of $980,000.00. Following the completion of the transaction, the chief financial officer directly owned 108,065 shares of the company’s stock, valued at approximately $10,590,370. This trade represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 113,792 shares of company stock worth $10,734,640. Insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in Revolution Medicines by 83.1% in the fourth quarter. Invesco Ltd. now owns 367,851 shares of the company’s stock valued at $29,299,000 after buying an additional 166,909 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Revolution Medicines in the fourth quarter valued at $215,000. ADAR1 Capital Management LLC raised its position in shares of Revolution Medicines by 4.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 145,079 shares of the company’s stock valued at $11,556,000 after purchasing an additional 5,943 shares during the period. Empowered Funds LLC bought a new stake in shares of Revolution Medicines during the 4th quarter worth about $77,000. Finally, KVP Capital Advisors LP bought a new stake in shares of Revolution Medicines during the 4th quarter worth about $2,190,000. Institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Revolution Medicines from $71.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Wolfe Research assumed coverage on Revolution Medicines in a research note on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Evercore raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: UBS initiated coverage with a “buy” rating, adding institutional validation and likely supporting investor demand. Tickerreport UBS Coverage
• Positive Sentiment: Evercore upgraded RVMD to “strong-buy,” another bullish analyst signal that can amplify upside momentum in the near term. Evercore Upgrade
• Positive Sentiment: Press and analyst write-ups are focusing on potential clinical progress — a Yahoo piece asks whether RVMD has a breakthrough in cancer treatment, which can fuel optimism about upcoming trial readouts and longer-term revenue potential if validated. Has Revolution Medicines Found a Breakthrough?
• Neutral Sentiment: Company release and investor materials for FY/Q4 2025 were posted (financial results and corporate update), providing the official detail behind the quarter and program status — useful for due diligence but largely informational. Company Press Release
• Neutral Sentiment: Earnings call transcript is available for investors to hear management’s detail on program timelines and the expense outlook; this helps assess execution risk but doesn’t change fundamentals by itself. Earnings Call Transcript
• Negative Sentiment: RVMD reported a wider-than-expected Q4 loss (EPS -$1.86 vs. consensus -$1.56) — an earnings miss that pressured near-term valuation multiple. MarketBeat Earnings Summary
• Negative Sentiment: Management now expects 2026 operating expenses of $1.6B–$1.7B to support late‑stage RAS programs — a large rise in cash burn that heightens funding and dilution risk absent clearer near‑term revenue or partnering. Zacks: Q4 Loss & 2026 Expense View

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.